BridgeMD
New treatment option for Prostate Cancer
Official title Designing Visual Tools to Enhance Cancer Surgeon Decision-making
ClinicalTrials.gov ID: NCT06965192
What this study is testing
- What it's testing
- This prospective study will compare pre-post pilot test of surgeon-facing, visual decision support among urologists seeing patients with newly diagnosed localized prostate and kidney cancer. Up to 20 urologists (10 academic and 10 community) will be enrolled.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- In order to participate in this study, a subject must meet all of the eligibility criteria outlined below.
- Verbal informed consent was obtained to participate in the study.
- Subject is willing and able to comply with study procedures based on the judgment of the investigator or protocol designee.
- Age ≥ 18 years at the time of consent.
- For patient people, HIPAA authorization for the release of personal health information and a new histologic diagnosis of localized prostate cancer...
You likely can't join if
- The people meeting the following criteria will be excluded from study participation:
- Non-English speaking.
- Unwilling or unable to complete informed consent.
- For patient people:
- Has staging information indicating locally advanced or metastatic disease. This would include PSA \>50 ng/ml, imaging suggestive of distant...
- Histologic or clinical diagnosis \>6 months before date of consent.
See the full eligibility criteria
- In order to participate in this study, a subject must meet all of the eligibility criteria outlined below.
- Verbal informed consent was obtained to participate in the study.
- Subject is willing and able to comply with study procedures based on the judgment of the investigator or protocol designee.
- Age ≥ 18 years at the time of consent.
- For patient people, HIPAA authorization for the release of personal health information and a new histologic diagnosis of localized prostate cancer based on prostate biopsy or clinical diagnosis of T1 renal mass (≤7 cm...
- For physician people, practicing urologist in North Carolina at UNC Health, Novant Health, or an affiliated site and sees patients with suspected or confirmed prostate or kidney cancer.
- The people meeting the following criteria will be excluded from study participation:
- Non-English speaking.
- Unwilling or unable to complete informed consent.
- For patient people:
- Has staging information indicating locally advanced or metastatic disease. This would include PSA \>50 ng/ml, imaging suggestive of distant metastasis, or lymph node involvement, renal masses \>7 cm or invading in renal...
- Histologic or clinical diagnosis \>6 months before date of consent.
The study team makes the final eligibility decision.
Where it's taking place
- Chapel Hill, North Carolina, United States
- Wilmington, North Carolina, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chapel Hill, North Carolina, United States; Wilmington, North Carolina, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.